ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings is supported by a leading global position in orthopedic reconstructive implants, with a broad large-joint franchise and meaningful exposure to extremities, trauma, and sports medicine, while the April 2025 Paragon 28 acquisition is already helping growth accelerate. 1Q26 net sales rose to $2,086.7 million, up 9.3% reported and 6.8% constant currency, and EPS of $2.09 beat expectations by about 12% as tariff refunds lifted margins, underscoring resilient underlying profitability. The ongoing distributor-to-direct salesforce transition, SKU rationalization, and new-product traction in hips and knees should support better execution, more consistent growth, and margin expansion over time.

Zimmer Biomet Holdings is exposed to meaningful downside because it is highly leveraged to reconstructive orthopedics, a market facing weak volume recovery, persistent pricing pressure, and intensifying competition from both established rivals and newer entrants with differentiated technology. Its 1Q26 results were complicated by two large account losses, the Kaiser Permanente nursing strike, and salesforce disruption, with US knees growth of only 2.2% versus broader US organic growth of 3.2%, while management said the channel overhaul will not be complete until the end of 2027. Although sales of $2.09B and EPS of $2.09 exceeded expectations, margins and EPS were aided by a one-time tariff refund benefit, and the company’s significant exposure to Europe and Asia adds geographic risk.